Urban S - Search Results

1

Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.

Blank A, Meier K, Urban S, Haefeli WE, Weiss J. Blank A, et al. Among authors: urban s. Antivir Ther. 2018;23(3):267-275. doi: 10.3851/IMP3206. Antivir Ther. 2018. PMID: 29134945

2

Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.

Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. Nkongolo S, et al. Among authors: urban s. J Hepatol. 2014 Apr;60(4):723-31. doi: 10.1016/j.jhep.2013.11.022. Epub 2013 Dec 1. J Hepatol. 2014. PMID: 24295872

3

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S. Ni Y, et al. Among authors: urban s. Gastroenterology. 2014 Apr;146(4):1070-83. doi: 10.1053/j.gastro.2013.12.024. Epub 2013 Dec 19. Gastroenterology. 2014. PMID: 24361467

4

Strategies to inhibit entry of HBV and HDV into hepatocytes.

Urban S, Bartenschlager R, Kubitz R, Zoulim F. Urban S, et al. Gastroenterology. 2014 Jul;147(1):48-64. doi: 10.1053/j.gastro.2014.04.030. Epub 2014 Apr 25. Gastroenterology. 2014. PMID: 24768844 Review.

5

Inhibitors of hepatitis B virus attachment and entry.

Lempp FA, Urban S. Lempp FA, et al. Among authors: urban s. Intervirology. 2014;57(3-4):151-7. doi: 10.1159/000360948. Epub 2014 Jul 15. Intervirology. 2014. PMID: 25034482 Free article. Review.

6

Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na(+)-taurocholate cotransporting polypeptide inhibitor.

Haag M, Hofmann U, Mürdter TE, Heinkele G, Leuthold P, Blank A, Haefeli WE, Alexandrov A, Urban S, Schwab M. Haag M, et al. Among authors: urban s. Anal Bioanal Chem. 2015 Sep;407(22):6815-25. doi: 10.1007/s00216-015-8853-5. Epub 2015 Jul 5. Anal Bioanal Chem. 2015. PMID: 26143062

7

A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B.

Uhl P, Helm F, Hofhaus G, Brings S, Kaufman C, Leotta K, Urban S, Haberkorn U, Mier W, Fricker G. Uhl P, et al. Among authors: urban s. Eur J Pharm Biopharm. 2016 Jun;103:159-166. doi: 10.1016/j.ejpb.2016.03.031. Epub 2016 Apr 2. Eur J Pharm Biopharm. 2016. PMID: 27049970

8

Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.

Li W, Urban S. Li W, et al. Among authors: urban s. J Hepatol. 2016 Apr;64(1 Suppl):S32-S40. doi: 10.1016/j.jhep.2016.02.011. J Hepatol. 2016. PMID: 27084034 Free PMC article. Review.

9

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Bogomolov P, et al. Among authors: urban s. J Hepatol. 2016 Sep;65(3):490-8. doi: 10.1016/j.jhep.2016.04.016. Epub 2016 Apr 27. J Hepatol. 2016. PMID: 27132170 Clinical Trial.

10

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. Blank A, et al. Among authors: urban s. J Hepatol. 2016 Sep;65(3):483-9. doi: 10.1016/j.jhep.2016.04.013. Epub 2016 Apr 27. J Hepatol. 2016. PMID: 27132172

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

524 results

Search Page

Filters